v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Product revenue $ 414 $ 317 $ 640 $ 362
Operating expenses:        
Cost of sales 391 302 597 335
Research and development 948 697 1,511 1,298
Sales and marketing 16 0 34 10
General and administrative [1] 751 1,151 1,796 2,222
Total operating expenses 2,106 2,150 3,938 3,865
Operating loss (1,692) (1,833) (3,298) (3,503)
Other (expense) income, net:        
Interest income 0 7 2 20
Interest expense (8) (3) (10) (5)
Other income 5 6 10 6
Other (expense) income, net (3) 10 2 21
Net loss $ (1,695) $ (1,823) $ (3,296) $ (3,482)
Basic and diluted net loss per share (in dollars per share) $ (0.1) $ (0.11) $ (0.19) $ (0.22)
Weighted average common shares outstanding, basic and diluted (in shares) 17,580,744 15,918,979 17,580,744 15,918,979
Comprehensive loss:        
Net loss $ (1,695) $ (1,823) $ (3,296) $ (3,482)
Foreign currency translation adjustments 1 (1) 5 (1)
Comprehensive loss $ (1,694) $ (1,824) $ (3,291) $ (3,483)
[1] Certain general and administrative costs (including executive compensation, corporate legal fees, audit fees, investor relations, and insurance) are shared across both segments. For internal reporting purposes, such costs are allocated to each segment based on an estimate of the proportion of management time and corporate resources utilized by each segment. Costs directly attributable to a segment are charged directly to that segment. For the three and six months ended June 30, 2026 and 2025, the Regenerative Biotech segment bore substantially all general and administrative expense, as the Consumer Health Products segment incurred minimal shared corporate overhead.